Chapman Christopher C JR 4

4 · MyMD Pharmaceuticals, Inc. · Filed Apr 21, 2021

Form 4

Period: 2021-04-16

DirectorPresident, Chief Med. Officer

Transactions

Award
Stock Option (Right to Buy)
2021-04-16+77,180→ 77,180 total
Exercise: $2.59Exp: 2023-04-16→ Common Stock (77,180 underlying)
Award
Stock Option (Right to Buy)
2021-04-16+77,180→ 77,180 total
Exercise: $2.59Exp: 2023-04-16→ Common Stock (77,180 underlying)
Award
Common Stock
2021-04-16+96,475→ 96,475 total
Award
Stock Option (Right to Buy)
2021-04-16+96,475→ 96,475 total
Exercise: $2.59Exp: 2023-04-16→ Common Stock (96,475 underlying)
Award
Stock Option (Right to Buy)
2021-04-16+38,590→ 38,590 total
Exercise: $2.59Exp: 2023-04-16→ Common Stock (38,590 underlying)

Footnotes (6)

[F1]Received in exchange for 250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.
[F2]Received in the Merger in exchange for a stock option to acquire 100,000 shares of common stock of the Former Entity at $1.00 per share.
[F3]These options are fully vested and exercisable.
[F4]Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.
[F5]Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.
[F6]Received in the Merger in exchange for a stock option to acquire 250,000 shares of common stock of the Former Entity at $1.00 per share.

Documents

1 file